For more than 15 years I am working the field of biomedical research and medical affairs in different indications for academic institutions and pharmaceutical companies. During that time I have learned that biological processes underlying different diseases are very similar in the way they interact with the physiological system. For example this is true for poxviruses when they use the same cell surface receptor for cellular spreading also responsible for initiating and maintaining tumor growth in some cancer patients, which is the epidermal growth factor receptor (EGFR). There are many more examples of this kind in virology, immunology and oncology. One detail in all of these interdependent interactions of "the good" and "the evil" is the fact that those diseases that are hardly curable seem to have the broadest repertoire of armory in terms of biological mechanisms. For those, only the combined inhibition of different targets lead to a significant improvement in favor of "the good". Such an example is the Human Immunodeficiency Virus (HIV) where the lack of a transcriptase proof-reading mechanism makes it impossible to design an effective vaccine or to generate a drug capable of clearing the virus from the body. However, quite a while after its discovery in the early 1980ies it became clear that only a combination therapy is able to provide a significant survival improvement for HIV infected patients. Taken together I am convinced that in many late stage cancer indications where patients do not have any more treatment options only an intelligent and biomarker-selected combination of targeted therapies will lead to an improvement. Today, I am employed at a pharmaceutical company and on the side I am still trying to fight cancer in a not for profit way by publishing and discussing hypotheses from my research and experiences at life-science-consulting.net.